(Q34794313)

4 August 2017

title

Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma (English)

1 reference

oral squamous cell carcinoma

4 August 2017

0 references

1 reference

1 reference

2

Ian Ganly

1 reference

4 August 2017

Alastair T M Mace

1

1 reference

4 August 2017

David S Soutar

series ordinal

3

1 reference

4 August 2017

S Moira Brown

series ordinal

4

1 reference

4 August 2017

publication date

1 August 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

30

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

1045-1051

1 reference

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)

4 August 2017

cites work

1 reference

7 January 2021

Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

1 reference

7 January 2021

Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17

1 reference

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

7 January 2021

Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS.

1 reference

7 January 2021

Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant

1 reference

7 January 2021

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

1 reference

7 January 2021

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

1 reference

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

7 January 2021

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

1 reference

7 January 2021

Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.

1 reference

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

7 January 2021

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

1 reference

7 January 2021

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

1 reference

7 January 2021

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

1 reference

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

7 January 2021

Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus

1 reference

7 January 2021

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

1 reference

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.20840

1 reference

4 August 2017

1 reference